DENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue fell 4.06%, EPS grew 181.8%, free cash flow grew 252.9% and total debt fell 10.0%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years; insiders bought in the last twelve months.
Follow XRAY
DENTSPLY SIRONA Inc. (XRAY) Altman Z-score
DENTSPLY SIRONA Inc.'s Altman Z-score for fiscal 2025 is 0.50, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 0.50 | (0.09) |
| FY2024 | 0.59 | (1.15) |
| FY2023 | 1.74 | 0.36 |
| FY2022 | 1.38 | (1.32) |
| FY2021 | 2.70 | 0.55 |
| FY2020 | 2.15 | (0.98) |
| FY2019 | 3.13 | 1.31 |
| FY2018 | 1.82 | (0.92) |
| FY2017 | 2.74 | (0.49) |
| FY2016 | 3.24 | (1.47) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.13 | — | 0.15 | |
| Retained earnings / total assets | (0.29) | — | −0.40 | |
| EBIT / total assets | (0.08) | — | −0.26 | |
| Market value of equity / total liabilities | 0.56 | — | 0.33 | |
| Sales / total assets | 0.68 | — | 0.68 | |
| Altman Z-score | Distress zone | 0.50 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −0.30 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| PLSE Pulse Biosciences, Inc compare | 31.4× |
| ATRC AtriCure, Inc. compare | 7.3× |
| LMAT LeMaitre Vascular, Inc. compare | 7.0× |
| STAA STAAR Surgical Company compare | 6.4× |
| WRBY Warby Parker Inc. compare | 4.7× |
| KMTS Kestra Medical Technologies, Ltd. compare | 3.9× |
| AZTA Azenta, Inc. compare | 3.9× |
| NVST Envista Holdings Corporation compare | 1.6× |
| XRAY DENTSPLY SIRONA Inc. | 0.5× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets